See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Rocket lays off staff; Abivax capitalizes on immune drug data

Summary by biopharmadive.com
The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck small research deals.

3 Articles

biopharmadive.combiopharmadive.com
Center

Rocket lays off staff; Abivax capitalizes on immune drug data

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck small research deals.

Read Full Article
stocktitan.netstocktitan.net

Abivax Scores Massive $747.5M Biotech Offering with 21% Premium as Underwriters Go All-In

Major confidence signal: Underwriters fully exercise option in Abivax's upsized offering, priced at 21% premium. See complete details of this landmark biotech raise.

Read Full Article
L'AGEFIL'AGEFI

Abivax Raises $650 Million, Following the Outbreak of Its Title

The capital increase is exclusively in the form of ADS, quoted on Nasdaq in New York, with a premium of 21% on the weighted average of the last three prices.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Thursday, July 24, 2025.
Sources are mostly out of (0)

Similar News Topics

News
For You
SearchBlindspotLocal